Experic talks about how biopharmaceutical companies can leverage CDMO collaborations to mitigate risks and maximize the benefits of key drug development decisions.
Find out how the NanoFlowSizer’s THALIA system is capable of measuring particle size in continuous liposome manufacturing with low lipid concentrations, below 3 mg/mL.
A convenient checklist from the experts at Experic to jump-start your planning so supply challenges won’t hinder your progress! Download the checklist today and take advantage of Experic's expert tips to optimize your clinical trial supply planning.
Discover how Experic's state-of-the-art spray drying service can control the formation of consistent particles for DPI therapeutics and increase control over the resulting properties of the powder.
By partnering with a specialized CDMO, a company can leverage its expertise, state-of-the-art facilities, and streamlined processes through the entire drug development journey.
A common obstacle life sciences organizations face during clinical trials is obtaining the right patients and promoting consistent engagement. High-quality data and technology can be used to streamline clinical trials and enable omnichannel experiences.
Modern mathematical and computerized modelling tools can improve scale-up and efficiency of continuous manufacturing of oral solid dosage drugs.
This whitepaper explores the criteria for defining true quality in a CDMO partnership, including multiple product, process, and relationship variables
Biotech, BioPharma’s, CDMOs, CROs who are investigating promising nucleic acid-based drug candidates like vaccines, mAbs, and other biologics & biosimilars must go through stringent quality control checks for their molecular entities to ensure safety & efficacy of their drug candidates. Explore the best quality control workflows using QualTrak qPCR ecosystems. Learn more inside this eBook about the benefits of:
Implementing a proper contamination control strategy (CCS) helps ensure product quality and patient safety. Additionally, it is a core element of good manufacturing practices.
Analytical Method Development for Synthetic Peptide Purity and Impurities Content by UHPLC - Illustrated Case Study
KBI Biopharma has created a platform E.coli resulting in a PURE, efficient platform expression strain - PUREcoli™ - to reduce impurities and reach higher titers.
This executive summary highlights strategies that can be used to maximize long-acting parenteral formulations using nanoparticles, microspheres and in-situ forming gels.
A company focused on the treatment of advanced solid tumors, partnered with Catalent for the development, clinical trial supply and scale-up of a spray-drying program.
Discover how to use enteric polymer coatings effectively for controlled drug delivery in oral medications to enhance your drug formulations.
In pursuit of increased competitiveness and bottom-line impact, pharmaceutical manufacturers face increasing pressure to fast-track technological innovation while maintaining regulatory compliance. This e-book explores how Artificial Intelligence (AI) can unlock new levels of insights into what is causing variation in processes that can wreak havoc on your drug manufacturing performance. Learn how to use AI so you can improve your manufacturing operations in GxP environments that are capable of delivering real returns on Pharma 4.0 technology initiatives.
How to Craft a Successful Orphan Drug Designation
Oligonucleotides are a class of biotherapeutics presenting complex challenges in the development and commercialization of gene therapies. Download our paper and learn how to move your project forward.
Speed is a critical factor in early-stage development. Solid state studies within an integrated CMC platform can support formulation development, accelerate timelines to Phase I clinical studies and increase the likelihood of successful clinical trial results.
Process equipment used in the healthcare and pharmaceutical industries follow rigid specifications for accuracy, consistency and cleanliness.
This case study shares why a leading biotech company reached out to Aizon to identify how artificial intelligence (AI) could be used to further optimize yield. The team was able to analyze five years of historical batch data to discover a direct correlation between hold up volume and time between process operations as well as generating millions of additional recovered revenue.
Real-world examples that demonstrate the value of using AI in GxP compliant manufacturing environments.
The lab of the future is about the whole enterprise. It generates business value by using advanced digital tools and techniques to make contextualized, actionable scientific data available at the bench, in the executive boardroom, and wherever that data can help generate revenue, accelerate innovation, and drive meaningful business decisions. This paper will help you keep up—and even get ahead—in a future that’s rapidly approaching.
The term “digital transformation” attracts a lot of hype. No wonder: the modern gleam of digital and the big-picture promise of that word transformation are irresistible. So much of that hype is based on speculation and inflated claims, though. This paper is your answer. It provides a hype-free account of three transformational projects undertaken in three intensely competitive industries.
The efficiencies and insights of artificial intelligence (AI), machine learning (ML), predictive analytics, and other emerging technologies offer abundant opportunities to laboratories. To help customers leverage digital transformation and prepare for the lab of the future, LabVantage Solutions has devised a five-step process for successfully implementing and profiting from AI in the lab.
From stumbling over a journal article in a library to developing a new form of analytical technology, Sean Hart, PhD, covered an exciting journey with laser force technology.
The increasing number of breakthroughs in small molecule drug development are exciting, but corresponding workflows are complex and require much more tailored approaches to ensure successful upstream and downstream processing, drug approvals and commercialization.
Enteric polymer coatings play a crucial role in oral drug formulations, protecting the active pharmaceutical ingredient (API) from harsh gastric conditions and enabling targeted drug delivery with optimized release based on location. By selecting enteric coatings, formulators can ensure the protection of their acid-sensitive APIs and create a controlled release drug delivery system. With the latest polymer coatings technology, there's no limit to the precision and adaptability that can be achieved in drug formulations. This white paper provides valuable insights into the successful application of enteric polymer coatings for controlled drug delivery systems. Discover how this innovative technology can transform your oral drug formulations.